Mouse Thyroid-Stimulating Hormone IgG ELISA Kit

Sample

Serum, plasma

Species Reactivity

Mouse

Detection Method

iELISA

Intended Use

The Mouse Thyroid-Stimulating Hormone IgG ELISA Kit is designed for the Semi-quantitative analysis of Mouse Serum, plasma samples.

Contents of Kit

1. Polystyrene microwell ELISA plates coated with a purified antigen(12-1 x 8 wells), with holder in foil package containing desiccants
2. Negative Control, 1 vial of buffer 1.2 mL
3. Positive Control, 1 vial of buffer 1.2 mL
4. Calibrator A, 1 vial of buffer containing preservative, prediluted, 1.2 mL
5. Calibrator B, 1 vial of buffer containing preservative, prediluted, 1.2 mL
6. Calibrator C, 1 vial of buffer containing preservative, prediluted, 1.2 mL
7. Calibrator D, 1 vial of buffer containing preservative, prediluted, 1.2 mL
8. Sample Diluent, 1 vial – colored straw containing PBS-buffered saline, protein stabilizers and preservative, 50 mL.
9. Antibody Enzyme Conjugate, colored blue containing buffer, protein stabilizers and preservative, 12 mL
10. Wash Buffer (20 ×), 50 mL
11. TMB Chromogen, containing stabilizers, 10 mL
12. Stop Solution, Colorless, 10 mL

Storage

2–8 °C, protected from light and moisture.

Detection Range

0 - 200 U

General Description

Graves' disease (GD) is an autoimmune disorder caused by the presence of thyroid stimulating immunoglobulins (TSI) that bind to the TSH receptor on the thyroid cells and stimulate the uncontrolled production of thyroid hormones. Detecting the presence of TSI in the blood is a powerful diagnostic tool for the differential diagnosis of GD.
TSI measurements are also used to monitor the response to GD therapy and prediction of remission or relapse, confirming Graves' ophthalmopathy, and for predicting neonatal thyroid hyperthyroidism. Incorporating the TSI assay into existing diagnostic algorithms has been shown to reduce overall direct costs of GD diagnosis by up to 43%, with the net cost of avoiding misdiagnosis reduced by up to 85%.
TSH receptor antibody (TRAb) assays detect both thyroid blocking and stimulating antibodies. However, blocking antibodies inhibit TSH stimulation of thyroid cells and lead to hypothyroidism.
The kit detects thyroid stimulating antibodies, the specific cause of GD pathology.

Glossary of terms
GD: Graves' Disease; an autoimmune disease that causes hyperthyroidism and is marked by some combination of tachycardia, fatigue, muscle weakness, heat intolerance, sleep disturbance, weight loss despite increased appetite and caloric consumption, ocular changes, visual disturbances, nervousness, irritability, depression, and mood swings.
TSH: Thyroid stimulating hormone; hormone released from the pituitary that stimulates the thyroid to produce and release thyroid hormones regulating metabolic homeostasis.
T3: Triiodothyronine; a thyroid hormone.
T4: Thyroxine; a thyroid hormone.
TSHR: Thyroid stimulating hormone receptor; activation by TSH or TSAbs results in the production and release of T3 and T4 from the thyroid.
TSAb: TSH receptor stimulating antibody; stimulates T3 and T4 release in the absence of TSH.
TBAb: TSH receptor blocking antibody; prevents TSH binding and stimulation of the TSH receptor, reducing the release of T3 and T4 by the thyroid.
HT: Hashimoto's thyroiditis; an autoimmune disease that causes hypothyroidism and is marked by goiter, weight gain, cold intolerance, fatigue, and constipation.
ELISA assay: The TSI ELISA, which uses genetically engineered chimeric TSH receptors lacking the primary TBAb binding site to capture and label TSAbs in serum samples. The Bridge assay is designed to reduce TBAb detection with the objective of more specifically detecting TSAbs.